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Recurrent and chronic respiratory tract infections in cystic fibrosis (CF) patients result in progressive 
lung damage and represent the primary cause of morbidity and mortality. Staphylococcus aureus 
(S. aureus) is one of the earliest bacteria in CF infants and children. Starting from early adolescence, 
patients become chronically infected with Gram-negative non-fermenting bacteria, and Pseudomonas 
aeruginosa (P. aeruginosa) is the most relevant and recurring. Intensive use of antimicrobial drugs 
to fight lung infections inevitably leads to the onset of antibiotic resistant bacterial strains. New 
antimicrobial compounds should be identified to overcome antibiotic resistance in these patients. 
Recently interesting data were reported in literature on the use of natural derived compounds that 
inhibited in vitro S. aureus and P. aeruginosa bacterial growth. Essential oils, among these, seemed to 
be the most promising. In this work is reported an extensive study on 61 essential oils (EOs) against 
a panel of 40 clinical strains isolated from CF patients. To reduce the in vitro procedure and render the 
investigation as convergent as possible, machine learning clusterization algorithms were firstly applied 
to pick-up a fewer number of representative strains among the panel of 40. This approach allowed us to 
easily identify three EOs able to strongly inhibit bacterial growth of all bacterial strains. Interestingly, 
the EOs antibacterial activity is completely unrelated to the antibiotic resistance profile of each strain. 
Taking into account the results obtained, a clinical use of EOs could be suggested.
Cystic fibrosis (CF), one of the most common lethal genetic disorders in Caucasian population, is inherited as 
an autosomal recessive disease and affects 70.000 persons worldwide (Cystic Fibrosis Foundation, CFF). The 
defective gene, identified in 1989, is the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that is 
carried by 4% of persons (among Caucasians). Since CFTR encodes for a chloride channel of the epithelial cell 
surface, CF patients manifest a variety of multi-organ problems due to the alteration of sodium and chloride 
secretion across cell membranes and the subsequent luminal dehydration1. The impairment of mucociliary clear-
ance, which should remove all microbes entering the airways, leads to the production of a thick and dehydrated 
mucus in the CF lung, which promotes the airway chronic bacterial colonization2.
The microbiology of CF respiratory tract is peculiar. In the early stage of life, it is characterized by the prev-
alence of the Gram-positive bacterium Staphylococcus aureus (S. aureus). Overall, in 2017 more than half of 
affected individuals had at least one culture positive for methicillin sensitive S. aureus (MSSA). The highest prev-
alence of methicillin resistant S. aureus (MRSA) occurs in individuals between the ages of 10 and 30, while MSSA 
reaches the peak among patients younger than 10 (Cystic Fibrosis Foundation. 2017. Patient Registry Annual 
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In early adolescence, CF patients’ lung becomes chronically infected with Gram-negative non-fermenting bac-
teria. Among these, Pseudomonas aeruginosa (P. aeruginosa) is the most relevant and recurring, so that 30% of CF 
children and up to 80% of CF adults (25 years old and older) have lungs chronically colonized by this pathogen3. 
P. aeruginosa isolated from respiratory secretions demonstrates great phenotypic diversity and develops genetic 
mutations over time to adapt and survive in the complex environment of the CF airway4. P. aeruginosa mucoid 
phenotype, defined by the exopolysaccharide alginate overproduction within lungs of CF patients, is a hallmark 
of chronic infection and predictive of poor prognosis. Indeed, mucoid P. aeruginosa has also been associated 
with failure of eradication and, compared to non-mucoid counterpart, exhibits enhanced resistance to multiple 
antibiotics and host immune effectors5.
Due to current therapeutic treatments, life expectancy for CF patients has consistently grown, reaching a 
median life of 40 years. Assuming a positive trend of clinical care improvements at the actual rate, CF patients 
born in 2010 are expected to live up to 50 years of age6.
The intensive use of antimicrobial drugs to fight lung infections inevitably leads to the onset of antibiotic 
resistant bacterial strains. New antimicrobial compounds should be identified to overcome antibiotic resistance 
during the treatment of CF lung infections.
Recent investigation has disclosed a few small molecules, such as peptides or mannosides, showing promising 
efficacy in prevention and treatment of both bacterial and fungal biofilm infection in vivo7. Nevertheless, due to 
their mechanism of action based on a specific binding to a main target, the use of small molecules is known to 
select more and more resistant strains8. Interestingly in the recent literature appeared some reports on the use 
of natural derived compounds that showed in vitro the potentiality to inhibit the development of CF associated 
infections9–12. In particular essential oils seemed to be the most promising agents among tested natural com-
pounds10,11. In this study is reported an extensive study on 61 essential oils (EOs) against a panel of 40 bacterial 
strains isolated from CF patients (see Table 1).
To reduce the in vitro procedure and to render the investigation as convergent as possible the following work-
flow was followed. Unsupervised machine learning algorithms and techniques, as implemented in python lan-
guage13, were firstly applied to pick-up a fewer number of representative strains (RS) among the panel of 40. To 
this aim, a number of categorical descriptors were collected and used to cluster the CF isolated strains. The clus-
ters’ centroids indicated the RS to be investigated for their susceptibility to a list of commercial EOs at fixed doses. 
Three EOs showed a great efficacy to reduce the microrganisms growth and were therefore promptly assayed 
against all the available clinical isolates. The three EOs confirmed the initial assumption demonstrating their 
ability to inhibit bacterial growth. Gas chromatography coupled with mass spectrometry (GC/MS) was then per-










6538P* STRONG PAO1* STRONG
25923* STRONG PA14* STRONG
1S WEAK 21P STRONG
2S MODERATE 22P NP
3S WEAK 23P MODERATE
4S WEAK 24P NP
5S WEAK 25P WEAK
6S WEAK 26P NP
7S MODERATE 27P NP
8S WEAK 28P NP
9S WEAK 29P NP
10S MODERATE 30P WEAK
11S WEAK 31P MODERATE
12S WEAK 32P WEAK
13S WEAK 33P NP
14S WEAK 34P WEAK
15S MODERATE 35P WEAK
16S WEAK 36P WEAK
17S MODERATE 37P STRONG
18S WEAK 38P MODERATE
19S WEAK 39P WEAK
20S MODERATE 40P WEAK
Table 1. Classification of bacterial strains based on their biofilm formation ability. For S. aureus, results were 
analysed according to Cafiso et al.14; for P. aeruginosa classification was based on Perez et al.15. NP: non biofilm 
producer. *Reference strains.
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Results
Characterization of biofilm formation of clinical bacterial strains. Clinical bacterial strains were 
investigated for their ability to produce biofilm (Fig. 1). Biofilm formation was evaluated at 37 °C in BHI for 18 h 
as described in Material and Methods section.
Biofilm formation was also evaluated for four reference strains included in the experimental plan. Figure 1A 
reports biofilm formation of bacterial strains belonging to S. aureus species. Clinical strains, named from 1S to 
20S, were classified as “weak” or “moderate” biofilm producers according to Cafiso and coworker, 200714. Both 
reference strains for S. aureus species are strong biofilm producers. Figure 1B reports biofilm formation of bac-
terial strains belonging to P. aeruginosa species. Clinical strains, named from 21P to 40P, were classified as: “non 
producer”, “weak”, “moderate” and “strong” biofilm producers according to Perez and Barth, 201115 (Table 1).
Selection of representative microorganisms by machine learning. The 40 selected strains were 
divided accordingly to the main strains families into S. aureus and P. aeruginosa dataset and imported into a 
python pandas dataframe. The principal components analysis (PCA) indicated that 90% of the variance is 
explained by the first 10th principal components (PCs) (Fig. 1S). Nevertheless graphical inspection of the PC1 
versus PC2 scores and loadings plots indicated the PCs as potential new variables to cluster the datasets (Fig. 2S). 
As a matter of fact, application of the Silhouette Analysis16 coupled with the k-means clustering17 to the first 2 
PCs indicated the optimal number of clusters to be 6 and 3 for the P. aeruginosa and S. aureus strains, respectively 
(Figs. 3S and 4S). For each cluster, the nearest datapoint to cluster centroid was selected yielding to a selection of 
representative strains to be screened with the commercial EOs. Analysis of data revealed the six samples, precisely 
22P, 25P, 26P, 27P, 37P and 39P as the representatives for P. aeruginosa, whereas samples 4S, 5S and 19S were 
selected for S. aureus.
Figure 1. Biofilm formation of S. aureus clinical and reference strains (A) and P. aeruginosa clinical and 
reference strains (B). The biofilm formation was evaluated after 18 h incubation in polystyrene plates at 37 °C. 
The data are reported as OD 590 nm after crystal violet staining. Each data point represents the mean ± SD of 
four independent samples.
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Antimicrobial activity of EOs on P. aeruginosa and S. aureus clinical strains from cystic fibrosis 
patients. Essential oils were tested for their ability to inhibit bacterial growth of P. aeruginosa and S. aureus 
clinical and reference strains. Analysis was performed on three representative S. aureus strains and six represent-
ative P. aeruginosa strains, previously selected by machine learning analysis. EOs were tested at a concentration 
of 1% v/v (Table 2). Several EOs have shown antimicrobial activity on many bacterial strains. It is worthy to note 
that the P. aeruginosa reference strain PAO1 is the most resistant to the action of EOs, since it was inhibited by 
only four EOs.
This analysis allowed to identify three EOs active against all the representative strains used, namely cade 
essential oil (22 in Table 2S, CEO), birch essential oil (32 in Table 2S, BEO) and Ceylon cinnamon peel essential 
oil (39 in Table 2S, CCPEO). Thus, these 22, 32 and 39 EOs were tested on all clinical bacterial strains. Results 
summarized in Table 3 confirmed that BEO, CEO and CCPEO exerted a strong and effective bactericidal potency 
on all tested clinical strains.
Chemical composition analysis of active selected essential oils. The results of GC and GC-MS analy-
ses of the essential oils are reported in Table 3S–5S. In the BEO, 21 components were identified and the major con-
stituents were δ-cadinene, calamenene and creosol (22.2%, 15.2% and 12.8% respectively) (Table 3S). The chemical 
composition of CCPEO was characterized by the presence of 19 compounds and by a high amount of cinnamalde-
hyde (49.4%) followed by eugenol (21.2%) (Table 4S). The chemical composition of the CEO indicated 21 compo-
nents and the most abundant were delta-cadinene (27.7%), calamenene (14.8%) and creosol (12.6%) (Table 5S). At 
first glance the chemical composition of the CEO seems very similar to that of BEO as the main compounds showed 
comparable percentages. Among the minor components of CEO, α-selinene (2.2%), aromadendrene (1.1%) and 
gleenol (1.1%) were found, whereas isoledene (5.7%) was found in BEO. At a deeper analysis the chemical qualitative 
profiles were compared and a 0.62 tanimoto index was calculated, thus indicating that although displaying a similar 
chromatogram the two EOs are indeed different. EOs producer was also inquired and their technical staff confirmed 
the two oils sharing high similarity quantitative profile in the main constituents.
Discussion
Long-term administration of antibiotics to prevent and treat airway infections in CF patients has been shown to 
be associated with the emergence of multi-drug (MDR) antimicrobial resistant microorganisms18.
In particular, mecA/mecC genes acquisition in S. aureus and accumulation of resistance mechanisms after 
antibiotic exposure in P. aeruginosa, both key pathogens in CF lung, are a concern in this context19,20.
Multidrug resistance significantly limits effective therapeutic options, affecting clinical outcome and prog-
nosis of patients. For this reason, the identification and development of new antibacterial agents is fundamental 
to improve survival and quality of life of individuals with CF. Therefore the development of antimicrobial agents 
provided with novel molecular mechanisms that may allow to control bacterial infectious diseases without diffus-
ing antibacterial resistance is desirable21.
Unsupervised Machine Learning algorithms13 applied to a panel of 40 strains of S. aureus and P. aeruginosa 
isolated from CF patients, led to select fewer representative strains using phenotypical and genotypical charac-
teristics as categorical descriptors. Therefore, the antibacterial activity of all tested EOs was initially assessed on 
9 selected bacterial strains: six representative strains for P. aeruginosa and 3 representative strains for S. aureus. 
The activity of all 61 EOs was also assessed on reference strains. Antimicrobial assays led to identify 3 EOs (CEO, 
BEO and CCPEO) out of the tested 61, that exhibited the highest antibacterial activity on the previously selected 
bacterial strains and reference ones. The antibacterial activity of the 3 selected EOs was then extended to all 
strains of both species. Interestingly all three EOs showed an utmost antimicrobial potency on all studied strains. 
Nothing can be yet ruled out on the chemical compounds’ role. Future studies involving machine learning appli-
cation10,11, will be devoted to investigate the importance of chemical constituent either on biofilm modulation or 
in antibacterial potencies.
Several papers aimed at elucidating the antimicrobial mechanism of action of EOs. For example, cinnamal-
dehyde, the major component of cinnamon, is able to disrupt the transmembrane potential of P. aeruginosa22.
Furthermore, EOs of different origin (lavender, lemongrass, marjoram, peppermint, tea tree and rosewood) 
show antimicrobial activity against Burkholderia cepacia complex by inducing changes in membrane fatty acid 
composition, followed by membrane disruption23. Also, EO from Alluaudia procera was active against S. aureus 
ATCC25923, a multi-resistant strain24. Reported data confirmed the possibility to use EOs as therapeutic strate-
gies in multi-resistant strains probably due to the heterogeneous composition of the oils themselves.
Notably, in this work we found EOs antibacterial activity unrelated to the antibiotic resistance profile of each strain.
This observation is of particular relevance as it suggests the EOs potential uses by topical administration with-
out taking into account the complexity of drug resistance profile of the microbiota in each single patient.
In conclusion the approach herein applied allowed to minimize the experimental steps and it was possible to 
identify the most promising EOs on the basis of probabilistic evaluations that confirmed their wide spectra of 
antibacterial potency with a reduced set of experiments.
From a literature survey (www.scopus.com, accessed 2019 December 13, keywords: essential oil, antibacterial 
activity and resistance) no evidence of resistance to EOs antibacterial activity has yet been reported. This is a char-
acteristic particularly relevant for antibacterial candidates to be administered for a chronic disease such as CF.
Indeed some papers report an increase of susceptibility to antibiotics after treatment with essential oils25,26.
Although a pletora of publications did not show development of resistance to EOs, a very recent publication 
suggested the induction of efflux pumps and multidrug resistance in P. aeruginosa by Cinnamaldehyde, the main 
component of cinnamon27. Therefore, in light of the recent reports, much still needs to be clarified on the effect of 
essential oils on bacterial multi-drug resistance.
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Eos ID 6538P 25923 4S 5S 19S PaO1 PA14 22P 25P 26P 27P 37P 39P
1 1% 1% 1%
2
3 1% 1%
4 1% 1% 1% 1% 1% 1% 1%
5
6 1% 1% 1% 1%
7
8
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Methods
Ethics approval and informed consent. The approval for this research was granted by the Ethics 
Committee of Children’s Hospital and Institute Research Bambino Gesù in Rome, Italy (No 1437_OPBG_2017 of 
July 2017), and it was performed according to the principles of the Helsinki Declaration. Informed consent was 
obtained from all individual participants and all parents/legal guardians included in the study.
Clinical isolates from CF patients. In this study were used 40 bacterial strains (20 S. aureus, 20 P. aerug-
inosa) obtained from respiratory specimens of 30 CF patients (13 males, 17 females; medium age 20.5) in 
follow-up at Pediatric Hospital Bambino Gesù (OPBG) of Rome, Italy. In particular, 27 bacterial strains were 
isolated from sputum, 11 from hypopharyngeal suction and 2 from throat swabs (Tables 4 and 5). As reference 
strains were used: S. aureus ATCC 6538P (6538P) and S. aureus ATCC 25923 (25923) commonly recognized as 
reference strains for antimicrobial testing; P. aeruginosa PAO1 (PAO1) and P. aeruginosa PA14 respectively recog-
nized as moderately and highly virulent28.
Patients were treated according to current standards of care29 with at least four microbiological controls per 
year. Informed consent was obtained from all subjects aged 18 years and older and from parents of all subjects 
under 18 years of age prior to enrolment.
Microbiological cultures have been performed according to approved Guidelines, using selective media, man-
ual and automatic systems (API20NE, Vitek2, MALDI-TOF mass spectrometry) for isolates identification and 
16S rRNA sequencing to assess ambiguous identifications.
The strains were selected from a local bacteria collection including about 10.000 CF bacterial isolates.




59 1% 1% 1% 1% 1% 1% 1%
60 1% 1% 1% 1%
61 1% 1% 1%
Table 2. Antimicrobial activity of EOs listed in Table 2S on representative clinical strains and reference strains 
of S. aureus and P. aeruginosa.
Bacterial strains CEO BEO CCPEO Bacterial strains CEO BEO CCPEO
ATCC6538P 1% 1% 1% PA O1 1% 1% 1%
ATCC25923 1% 1% 1% PA 14 1% 1% 1%
SA01 1% 1% 1% PA21 1% 1% 1%
SA02 1% 1% 1% PA22 1% 1% 1%
SA03 1% 1% 1% PA23 1% 1% 1%
SA04 1% 1% 1% PA24 1% 1% 1%
SA05 1% 1% 0.1% PA25 1% 1% 1%
SA06 1% 1% 1% PA26 1% 1% 1%
SA07 1% 1% 1% PA27 1% 1% 1%
SA08 1% 1% 1% PA28 1% 1% 1%
SA09 1% 1% 1% PA29 1% 1% 1%
SA10 1% 1% 1% PA30 1% 1% 1%
SA11 1% 1% 1% PA31 1% 1% 1%
SA12 1% 1% 1% PA32 1% 1% 1%
SA13 1% 1% 1% PA33 1% 1% 1%
SA14 1% 1% 1% PA34 1% 1% 1%
SA15 1% 1% 1% PA35 1% 1% 1%
SA16 1% 1% 1% PA36 1% 1% 1%
SA17 1% 1% 1% PA37 1% 1% 1%
SA18 1% 1% 1% PA38 1% 1% 1%
SA19 1% 1% 1% PA39 1% 1% 1%
SA20 1% 1% 1% PA40 1% 1% 1%
Table 3. Antimicrobial activity corresponding to minimal bactericidal concentration of previously selected 
EOs on all 40 clinical isolates.
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The species S. aureus and P. aeruginosa have been chosen for their clinical relevance in the natural history of 
CF disease, since they are related to a worst prognostic impact compared to other pathogens whose role is still 
under discussion.
In order to represent the complexity of CF lung microbiota population attending OPBG Center, a selection of 
specific strains with different phenotypic and biochemical features has been performed. The strains’ characteris-
tics are described in Tables 4 and 5.
Qualitative description of the clinical isolates. Twenty S. aureus strains with a different susceptibility 
profile, belonging to 20 CF patients, were selected: 10 Methicillin-Sensitive (MSSA) and 10 Methicillin-Resistant 
(MRSA). Among the MRSA strains, three S. aureus with phenotypic “small colony variants” (SCVs) have been 
chosen, characterized by slow growth of small, unpigmented, non-haemolytic colonies.
Antimicrobial susceptibility profiles of MSSA and MRSA isolates were defined by automatic system Vitek2 
(Biomerieux, France) or manual system E-test (Liofilchem, Italy). In particular, susceptibility to quinolones (cip-
rofloxacin, levofloxacin), trimethoprim/sulfamethoxazole, erythromycin, clindamycin, linezolid was assessed, 
according to EUCAST (www. EUCAST.org) criteria. Moreover, the clindamycin-inducing resistance test (40% 
positive test) was performed to classify S. aureus isolates that could develop acquired resistance to erythromycin 
or other macrolides during therapy with this antibiotic (Table 4)30.
Twenty P. aeruginosa isolates belonging to 11 CF patients were also selected (Table 5). The selected strains had 
been categorized as first, early and late isolates. In particular, seven strains have been associated to first acquisition 
of P. aeruginosa (first strains), 2 strains have been isolated 1 year after the first acquisition (early strains) and 11 
strains have been isolated at least 5 years after the onset of chronic colonization (late strains).
Moreover, different phenotypes (mucoid, wrinkle surface, irregular edges or smooth) and strains with differ-
ent antibiotic susceptibility patterns, e.g. P. aeruginosa producing Metallo-Beta-Lactamases (MBL)31 or P. aerugi-
nosa multi-drug resistant (MDR), have been selected.
Susceptibility testing to carbapenems (imipenem, meropenem), piperacillin/tazobactam, aminoglicosides 
(tobramycin, amikacin), quinolones (ciprofloxacin, levofloxacin), monobactam (aztreonam), and cephalospor-
ins (ceftazidime, cefepime) was carried out by Minimum Inhibitory Concentration (MIC) determined by E-test 
on Mueller Hinton (MH) agar plates, according to EUCAST criteria. The colistin MIC values were evaluated by 
Broth Microdilution (ComASP Colistin Liofilchem, Italy); 35% of P. aeruginosa isolates were MDR (i.e. resistant 
ID pt ID SAM Date Str Ph QUIN B ER CLI LIN RCLI CF CPA GEN
1 1S ESP 10/11/2006 MRSA SCV R S Nt R S N Cp J
2 2S ESP 11/22/2007 MRSA SCV R S Nt R S N Ca X N
3 3S ESP 1/15/2009 MRSA SCV S S Nt S S N X E
4 4S AT 2/20/2009 MRSA — S S Nt S S P A
5 5S ESP 11/13/2009 MRSA — R S Nt R S N Sp C
6 6S AT 1/10/2011 MRSA — R S Nt R S P K
7 7S ESP 4/4/2011 MRSA — R S Nt R S N Ca X D
8 8S AT 7/22/2013 MRSA — R S Nt S S N I
9 9S ESP 1/15/2014 MRSA — S S Nt R S P Ca X C
10 10S AT 1/29/2015 MRSA — S S Nt R S N Ca/Cd/Pb G
11 11S AT 6/15/2017 MSSA — S S R R S P C
12 12S AT 6/15/2017 MSSA — S S R R S P U
13 13S AT 5/23/2017 MSSA — I S I I S N Sa B
14 14S AT 5/25/2017 MSSA — S S S S S N C
15 15S AT 5/24/2017 MSSA — S S R S S N X C
16 16S AT 5/26/2017 MSSA — S S R R S N H
17 17S AT 5/25/2017 MSSA — S S R R S N Af M
18 18S ESP 5/24/2017 MSSA — S S R R S P Ca X C
19 19S ESP 6/15/2017 MSSA — S S R R S P X L
20 20S ESP 5/19/2017 MSSA — R S R R S P X F
Table 4. The 20 Staphylococcus aureus clinical isolates and their characterization by several properties. ID 
pt: patient identification; ID: strain code; SAM:Sample; Date: Date of collection; Str:Strain; Ph: phenotype; 
QUIN: quinolones; B: Trimethoprim/Sulfamethoxazole; ER: Erythromycin; CLI: Clindamycin; LIN: linezolid; 
RCLI: Inducible Clindamycin resistance; CF: Fungal Co-infection; CPA: P. aeruginosa co-infection; GEN: pts 
genotype; Esp: sputum; AT: hypopharyngeal suction; MRSA: Methicillin Resistant S. aureus; MSSA: Methicillin 
Sensitive S. aureus; SCV: Small colony variant; R: Resistant;S: Susceptible; I: Intermediate; N: Negative; Nt: non-
tested; Af: Aspergillus fumigatus; Ca: Candida albicans; Cp: Candida parapsilosis; Sp: Scedosporium prolificans; 
Cd: Candida dubliniensis; Pb: Pseudoallescheria boydii; Sa: Scedosporium apiospermum. X: denotes positive for 
this feature; -: denotes common phenotype. See Table 6 showing the correlation between letter code, CFTR gene 
mutation of the patient and bacterial strain isolated from the same patient.
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to three or more classes of antimicrobials)32 (Table 3). Table 1 of Supplementary Materials reports the percentage 
of bacterial strains resulted sensitive or resistant to different classes of antibiotics here tested (Table 1S).
Co-infection by bacterial (P. aeruginosa/S. aureus) and fungal agents (Aspergillus fumigatus/Candida albicans/
Candida parapsilosis/Candida dubliniensis/Candida lusitaniae/Scedosporium prolificans/Scedosporium apiosper-
mum//Pseudoallescheria boydii) was also evaluated for each patient (Tables 4 and 5).
Table 6 reports letters’ code correspondence for the strains associated genotype reported in Tables 4 and 5.
Biofilm production assay. The quantification of biofilm production was based on microtiter plate biofilm 
assay (MTP) as reported in literature12. Briefly, the wells of a sterile 96-well flat-bottomed polystyrene plate were 
filled with 100 µL of the appropriate medium. 1/100 dilution of overnight bacterial cultures was added into each 
well (about 0.5 OD 600 nm). The plates were incubated aerobically for 18 h at 37 °C. Biofilm formation was meas-
ured using crystal violet staining. After incubation, planktonic cells were gently removed; each well was washed 
three times with double-distilled water and patted dry with a piece of paper towel in an inverted position. To 
quantify biofilm formation, each well was stained with 0.1% crystal violet and incubated for 15 min at room tem-
perature, rinsed twice with double-distilled water, and thoroughly dried. The dye bound to adherent cells was sol-
ubilized with 20% (v/v) glacial acetic acid and 80% (v/v) ethanol. After 30 min of incubation at room temperature, 
OD590 was measured to quantify the total biomass of biofilm formed in each well. Each data point is composed 
of 4 independent experiments, each performed at least in 6-replicates.
Statistical analysis of biological evaluation. Data reported were statistically validated using Student’s 
t-test comparing mean absorbance of treated and untreated samples. The significance of differences between 
mean absorbance values was calculated using a two-tailed Student’s t-test. A p value of <0.05 was considered 
significant.
ID pt ID SAM date Str Ph CAR PTC AM QUIN MB CEF COL 1St E L CF CSA GEN
21 21P ESP 8/8/2006 PA MDR s R R R R R R S X E
21 22P ESP 1/11/2017 PA MDR w R S R R S R S X E
22 23P ESP 6/24/2005 PA MDR MBL+ sm R S R R S R S X B
22 24P ESP 3/27/2017 PA MDR MBL+ s R S R R S R S X Ca/Cl B
23 25P AT 9/3/2010 PA sm S S I S I S S X B
24 26P TF 8/27/2008 PA i S S S S I S S X G
24 27P AT 1/31/2017 PA sm S S S S S S S X X G
25 28P ESP 5/24/2012 PA sm S S S S S S S X U
25 29P AT 9/13/2017 PA m S S S S S S S X U
9 30P ESP 9/6/2010 PA i S S S S I S S X B
9 31P ESP 1/11/2017 PA m S S S R S S S X X B
26 32P AT 12/5/2006 PA sm S S R S I S S X F
26 33P AT 12/28/2016 PA m S S S S I S S X Ca X F
27 34P ESP 5/11/2005 PA i MP I/IP R S S
CI S/
LE R I S S X Ca D
27 35P ESP 3/29/2017 PA MDR sm R R R R I R S X D
28 36P TF 2/11/2008 PA sm S S S S I S S X A
28 37P AT 2/22/2017 PA m MP S/IP R S R S S R S X A
29 38P ESP 3/7/2006 PA MDR s R R R R R R S X B
29 39P ESP 1/25/2017 PA MDR m R R R R I R S X B
30 40P AT 7/1/2013 PA i S S S S S S S X Ca X C
Table 5. The 20 Pseudomonas aeruginosa clinical isolates and their characterization by several properties. ID pt: 
patient identification;ID: strain code;SAM: Sample; Date: Date of collection; Str: Strain; Ph: Phenotype; CAR: 
Carbapenems; MP: Meropenem; IP: Imipenem; PTC: Piperacillin/tazobactam; AM: Aminoglycosides; QUIN: 
Quinolones; CI: Ciprofloxacin; LE: Levofloxacin; MB: Monobactam; CEF: Cephalosporins; COL: Colistin; 1 St: 
P. aeruginosa first isolate; E: P. aeruginosa early isolate; L: P. aeruginosa late isolate; CF: Fungal co-infection; CSA: 
S. aureus co-infection; Gen: pts genotype; BP: Biofilm Producer; Esp:sputum; AT: hypopharyngeal suction; 
TF: throat swabs; PA: P. aeruginosa; PA MDR: P. aeruginosa multi-drug resistant; PA MBL+: P. aeruginosa 
Metallo-Beta-Lactamases producing; s: small colony phenotype; w- wrinkled colony surface; m: mucoid colony; 
i: irregular colony edges; sm: smooth phenotype; R: Resistant; S: Susceptible; I: Intermediate; CA: Candida 
albicans; CL: Candida lusitaniae; X: denotes positive for the feature. See Table 6 showing the correlation between 
letter code, CFTR gene mutation of the patient and bacterial strain isolated from the same patient.
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Chemical composition analysis of active selected essential oils. EOs were purchased from 
Farmalabor srl (Assago, Italy) and analyzed to characterize their composition as following.
Chemical analyses of EOs were performed by a Turbomass Clarus 500 GC-MS/GC-FID from Perkin Elmer 
instruments (Waltham, MA, USA) equipped with a Stabilwax fused-silica capillary column (Restek, Bellefonte, 
PA, USA) (60 m × 0.25 mm, 0.25 mm film thickness). The operating conditions used were as follows: GC oven 
temperature was kept at 40 °C for 5 min and programmed to 220 °C at a rate of 6 °C/min, and kept constant at 
220 °C for 20 min. Helium was used as carrier gas (1.0 mL/min). Solvent delay 0–2 min and scan time 0.2 s. Mass 
range was from 30 to 350 m/z using electron-impact at 70 eV mode. 1 μL of each essential oil was diluted in 1 mL 
of methanol and 1 μL of the solution was injected into the GC injector at the temperature of 280 °C. Relative per-
centages for quantification of the components were calculated by electronic integration of the GC-FID peak areas. 
The identification of the constituents was achieved by comparing the obtained mass spectra for each component 
with those reported in mass spectra Nist and Wiley libraries. Linear retention indices (LRI) of each compound 
were calculated using a mixture of aliphatic hydrocarbons (C8-C30, Ultrasci) injected directly into GC injector at 
the same temperature program reported above.
Code Genotype ID strain
A 621+1G > T/R553X 4S











H F508del/R117L + L997F 16S
I F508del/R585X 8S
J F508del/W1282X 1S

















E N1303K/3849 + 10kbC > T 21P
E N1303K/3849 + 10kbC > T 22P
F R347P/L571S 32P
F R347P/L571S 33P
G W1282X/2789 + 5G- > A 26P
G W1282X/2789 + 5G- > A 27P
U None 28P
U None 29P
Table 6. Table shows the correlation between letter code, CFTR gene mutation of the patient and bacterial 
strain isolated from the same patient.
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Determination of EOs minimal inhibitory concentration (MIC). The MIC was determined as the 
lowest concentration at which the observable bacterial growth was inhibited. MICs were determined according 
to the guidelines of Clinical Laboratory Standards Institute (CLSI33). Each EO was solubilized by adding DMSO, 
to generate a mother stock solutionof 1 g/mL. Appropriate dilution (106 cfu/mL) of bacterial culture in expo-
nential phase was used. Antimicrobial activity of each EO was evaluated at a concentration of 1 mg/mL range. 
Experiments were performed in quadruplicate.
Unsupervised machine learning clusterization of clinical isolates
The cluster analysis was implemented in the Python (version 3.6) programming language13. The S. aureus and P. 
aeruginosa datasets were imported in a jupyter-notebook (version 5.7)34 and the categorical variables loaded into 
a Pandas35 dataframe were transformed into dummy indicator variables for the subsequent Principal Component 
Analysis (PCA) using the utilities available in the Pandas (version 0.23) library. The PCA analysis was performed 
using the scikit-learn library (version 0.20)36 to extract the first 20 principal components (PCs, Fig. 1S). The scores 
and loadings were graphically inspected on plots generated using the matplotlib library (version 3.0)37 (Fig. 2S). 
The PCs were used as features for the k-means clusterization. Silhouette analysis16 was performed to evaluate 
the separation distance between the resulting clusters and choose an optimal value for the number of clusters. 
Optimal number of clusters was identified by the maximum silhouette scores as graphically reported in Fig. 3S. 
Through k-means, the centroid of each cluster was calculated and the closest datapoint directly indicated the RS 
(Fig. 4S).
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